|GRANTWAY
EN

HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)

National Institutes of Health

Share
Favorite
Feedback
Summary
-
17 June 2025
-
-
-
For profit
Not for profit (incl. NGOs)
Public sector
R&D and Higher Education
United States of America
Education, Skills Building and Training Health, Justice and Social Welfare
Research, Development and Innovation Medical and Health Sciences
Overview

The purpose of this Funding Opportunity Announcement (FOA) is to develop clinical-grade prototypes intended for use as safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use.

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
20 April 2023